A practical reference on hexenoyl cap: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-29. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Glycolipid transfer protein is a cytosolic protein that catalyses the transfer of glycolipids between different intracellular membranes. It was discovered by Raymond J. Metz and Norman S. Radin in 1980 and partially purified and characterized in 1982. Recent reviews on structure and possible function are available. This protein transports primarily different glycosphingolipids and glyceroglycolipids between intracellular membranes, but not phospholipids. It might be also involved in translocation of glucosylceramides. It was found in brain, kidney, spleen, lung, cerebellum, liver and heart.
diffusion The net movement of atoms or molecules from a region of higher concentration to a region of lower concentration. Diffusion is driven by a gradient in chemical potential of the diffusing species and depends on the random walk of particles; hence it results in mixing or mass transport without required directed bulk motion.
England and Wales Samuel Benjamin Allison, Station Manager, Dorset and Wiltshire Fire and Rescue Service Phillip Garrigan, , Chief Fire Officer, Merseyside Fire and Rescue Service Andrew Roe, London Fire Commissioner, London Fire Brigade David Jonathan Russel, Chief Fire Officer, Greater Manchester Fire and Rescue Service Scotland David Gibson, Watch Commander, Scottish Fire and Rescue Service. Iain Morris, Acting Director, Asset Management, Scottish Fire and Rescue Service. Northern Ireland Thomas Stanley Torbitt, Watch Commander, Northern Ireland Fire and Rescue Service
Sources: en.wikipedia.org
== Steady state == The steady state or stable concentration is reached when the drug's supply to the blood plasma is the same as the rate of elimination from the plasma. It is necessary to calculate this concentration in order to decide the period between doses and the amount of drug supplied with each dose in prolonged treatments.
Chronic Somogyi rebound is a contested explanation of phenomena of elevated blood sugars experienced by diabetics in the morning. Also called the Somogyi effect and posthypoglycemic hyperglycemia, it is a rebounding high blood sugar that is a response to low blood sugar. When managing the blood glucose level with insulin injections, this effect is counter-intuitive to people who experience high blood sugar in the morning as a result of an overabundance of insulin at night. This theoretical phenomenon was named after Michael Somogyi [suh MOE jee], a Hungarian-born professor of biochemistry at the Washington University and Jewish Hospital of St. Louis, who prepared the first insulin treatment given to a child with diabetes in the US in October 1922. Somogyi showed that excessive insulin makes diabetes unstable and first published his findings in 1938. Compare with the dawn phenomenon, which is a morning rise in blood sugar in response to waning insulin and a growth hormone surge (that further antagonizes insulin).
== Classification == An internationally agreed classification formulated at the World Workshop in Clinical Periodontics in 1989 divided periodontal diseases into 5 groups: adult periodontitis, early-onset periodontitis, periodontitis associated with systemic disease, necrotizing ulcerative periodontitis and refractory periodontitis. In 1993 at the 1st European Workshop in Periodontology the earlier classification was simplified and the categories periodontitis associated with systemic disease and refractory periodontitis were dropped. Both of these classification systems were widely used in clinical and research settings. However, they failed to address a gingival disease component, had overlapping categories with unclear classification criteria and over focussed on age of onset and rate of disease progression. Consequently, a new classification was developed at the International Workshop for a Classification of Periodontal Diseases and Conditions in 1999. This covered in much more detail the full range of periodontal diseases. "Adult periodontitis" was reclassified "chronic periodontitis" and "early-onset periodontitis" to "aggressive periodontitis". This article follows the 1999 classification, although the ICD-10 (10th revision of the International Statistical Classification of Diseases and Related Health Problems) differs significantly. The latest World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions was held in 2017. this updated classification overcomes some of the limitations of its predecessors, including:
Sources: en.wikipedia.org
=== Portugal === In Portugal, a resident physician is one undergoing postgraduate training aimed at obtaining a medical specialty. This training period begins after completing medical school and can last between 5 and 7 years, depending on the chosen specialty. At the end of their residency, physicians attain the status of specialist. The Medical Residency in Portugal is regulated by Decree-Law No. 60/2007, of March 13, and by Ordinance No. 183/2006, of February 22 (Medical Residency Regulation). It is organized into two training periods: the Common Year and the Professional Specialization Area. Until 2004, the residency was divided into General (2 years) and Complementary (3 to 6 years) phases. Upon completing medical school, doctors apply to a national competition for admission into the Medical Residency. This competition determines their placement for training locations and specialties, prioritizing the score obtained in a national ranking exam (a test with one hundred questions and five multiple-choice answers). The second criterion, used only in cases of a tie, is the medical school final grade. There is frequent confusion between a resident physician and an internal medicine specialist, also known as an internist. These terms are not synonymous, even though a resident physician may be pursuing specialization in internal medicine. The Portuguese Medical Association is the entity that regulates medical practice in Portugal, ensuring the technical-scientific postgraduate training of its members through residency programs, which grant physicians specialist status.
== Cis/trans isomers of the peptide group == Significant delocalisation of the lone pair of electrons on the nitrogen atom gives the group a partial double-bond character. The partial double bond renders the amide group planar, occurring in either the cis or trans isomers. In the unfolded state of proteins, the peptide groups are free to isomerize and adopt both isomers; however, in the folded state, only a single isomer is adopted at each position (with rare exceptions). The trans form is preferred overwhelmingly in most peptide bonds (roughly 1000:1 ratio in trans:cis populations). However, X-Pro peptide groups tend to have a roughly 30:1 ratio, presumably because the symmetry between the Cα and Cδ atoms of proline makes the cis and trans isomers nearly equal in energy, as shown in the figure below.
serine + tetrahydrofolate → glycine + N5,N10-methylene tetrahydrofolate + H2O In E. coli, antibiotics that target folate depletes the supply of active tetrahydrofolates, halting glycine biosynthesis as a consequence. In the liver of vertebrates, glycine synthesis is catalyzed by glycine synthase (also called glycine cleavage enzyme). This conversion is readily reversible:
== GBS infection in adults == GBS is also an important infectious agent able to cause invasive infections in adults. Serious life-threatening invasive GBS infections are increasingly recognized in the elderly and individuals compromised by underlying diseases such as diabetes, cirrhosis and cancer. GBS infections in adults include urinary tract infection, skin and soft-tissue infection (skin and skin structure infection) bacteremia, osteomyelitis, meningitis, and endocarditis.GBS infection in adults can be serious and is associated with high mortality. In general, penicillin is the antibiotic of choice for the treatment of GBS infection. Gentamicin (for synergy with penicillin G or ampicillin) can also be used in patients with life-threatening invasive GBS.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.